Article
Washington, D.C. - The Prescription Drug User Fee Act of 1992 reducedthe time the U.S. Food and Drug Administration needs to review and approvenew pharmaceuticals, said the Tufts Center for the Study of Drug Development.
Elevate-Derm West Conference 2024 Recap
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Reviewing Multiple Subtypes of CHE and Delgocitinib as a Pan-JAK Inhibitor
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Exploring the Atopic Dermatitis Treatment Paradigm and Challenging Cases
Pediatric Melanoma in Review: Providing Considerations for Dermatologists